Chewy vs. Five Below: Which Retailer Stock Is a Better Buy for 2027?

The article favors Five Below for 2027, citing its 18% same-store sales growth in the first half of fiscal 2027, a plan to open 150 stores annually, and a forward P/E of 23.5x versus Chewy’s 27.5x. Analysts expect Five Below’s fiscal 2027 revenue to rise 20% to $5.17 billion and net income to increase at least 40% to about $360 million, though tariffs, inventory shrinkage, and lawsuits remain risks. Chewy offers recurring Autoship sales and expanding pet-health services, with fiscal 2026 consensus estimates of $13.5 billion in sales and $333 million in net income, but the article points to its thinner margins and competitive pressures.

Analysis

The relative case favors FIVE only if recent demand translates into durable, cash-generative store growth—not simply because its forward P/E is lower. The key market mechanism is operating leverage: sustained comparable-store sales and successful new-store cohorts can lift earnings faster than revenue. But a rapid opening cadence also raises the risk that prime locations get exhausted, paybacks lengthen, or tariff-related costs hit margins with a lag. Treat management’s store-payback claim and margin resilience as claims to verify against cohort returns, lease-adjusted investment, and gross-margin guidance.

CHWY offers a different, less location-dependent growth option: recurring orders may stabilize demand, while pharmacy and veterinary services could improve monetization. That upside is not yet proof of a moat; clinic integration and competitive pricing could absorb the benefit. Its reported cash generation also deserves a quality check given the article’s stated stock-compensation contribution. Avoid comparing the companies’ headline margins without accounting for their very different business models.

Near term, FIVE’s reported sales momentum may support relative performance, but expectations already embed substantial growth. Over 1–3 months, watch comparable sales, gross margin, tariff pass-through, and new-store returns. Over 6–18 months, the thesis depends on whether expansion compounds without deteriorating unit economics. A sharp sales deceleration, margin contraction, or lengthening payback would undermine FIVE; improving CHWY service economics and cash conversion would narrow the relative gap. The supplied figures span different fiscal periods, so reconcile the latest filings before sizing.

Key Decisions for Investors

• Prefer a measured long FIVE over a fresh outright CHWY long for growth exposure, but do not chase a momentum spike; add only if the next results confirm comparable-sales durability and stable gross margin.
• A relative-value expression is long FIVE / short CHWY at conservative size, with the short leg treated as a hedge rather than a standalone call. Reassess if CHWY demonstrates improving service contribution and cash conversion, or if FIVE’s unit economics weaken.
• Use FIVE’s next earnings and store-cohort disclosures as the 1–3 month catalyst check: verify comparable-sales composition, tariff effects, inventory shrink, and payback after occupancy and distribution costs. The article’s reported payback and growth estimates are not independently validated here.
• Falsify the FIVE thesis on a sustained comparable-sales slowdown, gross-margin reversal, or evidence that new-store returns are deteriorating; for CHWY, watch whether clinic integration costs persist without measurable service-led improvement. Reconcile fiscal periods and cash-flow/SBC treatment against filings before acting.